ConductScience.org, home

Paper28577239

Population pharmacokinetic analyses of the effect of carboplatin pretreatment on olaparib in recurrent or refractory women's cancers.

Peer CJ and 8 others. Cancer Chemother Pharmacol, 2017. Cited by 10 papers, by iCite.

Cite this record

ConductScience Library. Population pharmacokinetic analyses of the effect of carboplatin pretreatment on olaparib in recurrent or refractory women's cancers. Papers, record 28577239. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28577239

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Population pharmacokinetic analyses of the effect of carboplatin pretreatment on olaparib in recurrent or refractory women's cancers.
PubMed
Journal
Cancer Chemother Pharmacol
PubMed
Year
2017
PubMed
Publication types
Clinical Trial, Phase I, Journal Article
PubMed
Citations, by iCite
10
iCite
Relative citation ratio, by iCite
0.28
iCite
Revised in PubMed
2025-05-30
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Peer CJCody J
2Lee JMJung-Min
3Roth JJeffrey
4Rodgers LLouis
5Nguyen JJeffers
6Annunziata CMChristina M
7Minasian LLori
8Kohn ECElise C
9Figg WDWilliam D

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
CarboplatinMajor topic
Models, BiologicalMajor topic
PhthalazinesMajor topic
PiperazinesMajor topic
Adult
Aged
Breast Neoplasms
Drug Administration Schedule
Drug Interactions
Female
Genital Neoplasms, Female
Humans
Middle Aged
Tissue Distribution

Source PubMed

Download CSV of topics

Grants3

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
Z01 BC010548Intramural NIH HHSUnited StatesZICBC010548PubMed and NIHNIH RePORTER
ZIABC011525NIHNIH RePORTER
ZICSC006537NIHNIH RePORTER

Download CSV of grants

References32

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
112470990The relationship between the roles of BRCA genes in DNA repair and cancer predisposition.Trends Mol Med2002https://conductscience.org/library/papers/12470990PubMed
216696564Kinetics of carboplatin-DNA binding in genomic DNA and bladder cancer cells as determined by accelerator mass spectrometry.Chem Res Toxicol2006https://conductscience.org/library/papers/16696564PubMed
319553641Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.N Engl J Med2009https://conductscience.org/library/papers/19553641PubMed
420406929Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.J Clin Oncol2010https://conductscience.org/library/papers/20406929PubMed
520609467Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.Lancet2010https://conductscience.org/library/papers/20609467PubMed
620609468Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.Lancet2010https://conductscience.org/library/papers/20609468PubMed
721590367Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study.Invest New Drugs2012https://conductscience.org/library/papers/21590367PubMed
821862407Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.Lancet Oncol2011https://conductscience.org/library/papers/21862407PubMed
922145984A Phase I, dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors.Cancer Sci2012https://conductscience.org/library/papers/22145984PubMed
1022203755
Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer.
J Clin Oncol2012https://conductscience.org/library/papers/22203755PubMed
1122223088Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours.Br J Cancer2012https://conductscience.org/library/papers/22223088PubMed
1222371451A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors.Clin Cancer Res2012https://conductscience.org/library/papers/22371451PubMed
1322452356Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.N Engl J Med2012https://conductscience.org/library/papers/22452356PubMed
1423239809Synergistic effect of olaparib with combination of cisplatin on PTEN-deficient lung cancer cells.Mol Cancer Res2013https://conductscience.org/library/papers/23239809PubMed
1523315029Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a phase I multicentre trial in patients scheduled for elective breast cancer surgery.Invest New Drugs2013https://conductscience.org/library/papers/23315029PubMed
1623810467
A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer.
Eur J Cancer2013https://conductscience.org/library/papers/23810467PubMed
1724063698Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer.Breast Cancer Res2013https://conductscience.org/library/papers/24063698PubMed
1824827126Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors.Ann Oncol2014https://conductscience.org/library/papers/24827126PubMed
1924842883Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses.J Natl Cancer Inst2014https://conductscience.org/library/papers/24842883PubMed
2024882434Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.Lancet Oncol2014https://conductscience.org/library/papers/24882434PubMed

See all 32 referencesDownload CSV of references

Cited by8

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 10 citations.

PMIDTitleJournalYearIn PapersSource
37345149Cross-Resistance between Platinum-Based Chemotherapy and PARP Inhibitors in Castration-Resistant Prostate Cancer.Cancers (Basel)2023https://conductscience.org/library/papers/37345149PubMed
36672401DNA Damage Response Alterations in Ovarian Cancer: From Molecular Mechanisms to Therapeutic Opportunities.Cancers (Basel)2023https://conductscience.org/library/papers/36672401PubMed
36219340Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology.Clin Pharmacokinet2022https://conductscience.org/library/papers/36219340PubMed
36077867PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and Beyond.Cancers (Basel)2022https://conductscience.org/library/papers/36077867PubMed
34451901Association between Olaparib Exposure and Early Toxicity in BRCA-Mutated Ovarian Cancer Patients: Results from a Retrospective Multicenter Study.Pharmaceuticals (Basel)2021https://conductscience.org/library/papers/34451901PubMed
33627685A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors.Sci Rep2021https://conductscience.org/library/papers/33627685PubMed
30357650Bridging Olaparib Capsule and Tablet Formulations Using Population Pharmacokinetic Meta-analysis in Oncology Patients.Clin Pharmacokinet2019https://conductscience.org/library/papers/30357650PubMed
29717476Physiologically Based Pharmacokinetic Modeling for Olaparib Dosing Recommendations: Bridging Formulations, Drug Interactions, and Patient Populations.Clin Pharmacol Ther2019https://conductscience.org/library/papers/29717476PubMed

Download CSV of cited by

Genes4

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
BRCA1672PubTator's text mininghttps://conductscience.org/library/genes/672NCBI Gene
BRCA2675PubTator's text mininghttps://conductscience.org/library/genes/675NCBI Gene
PARP1142PubTator's text mininghttps://conductscience.org/library/genes/142NCBI Gene
VEGFA7422PubTator's text mininghttps://conductscience.org/library/genes/7422NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/28577239

GET https://conductscience.org/api/papers/v1/28577239/references?page=2